LIX1 and gastrointestinal stromal tumor: To determine whether MAPK-signaling reactivation in imatinib-treated cells requires LIX1, we used GIST-T1 cell lines that stably express negative control shRNA (GIST-T1-Scramble) or two different shRNAs against LIX1 (GIST-T1-ShLIX1#1 and GIST-T1-ShLIX1#2) [29].